tions difficult to differentiate from those caused by prolapse of a cervical intervertebral disc. Both conditions may cause considerable pain, with reluctance to move the head and protective spasm of the neck muscles. Both tumour and prolapsed disc may cause peripheral nerve dysfunction, with flaccid paralysis of the affected foreleg and neurogenic atrophy as well as hindleg paralysis because of pressure necrosis of the cord. However, remissions can be expected with a prolapsed disc whereas tumour progresses to its fatal outcome.
The morphological differentiation of primary neoplasms of the CNS in the dog is complex. Many tumours such as meningiomas, schwannomas, oligodendrogliomas and glioblastomas resemble closely their counterparts in man. But in the case of many gliomas and of a wide range of meningeal sarcomas and neoplastic reticuloses no human tumours appear to be analogous, and this has led to much confusion in classification (see Luginbuhl et al. 1968 ).
Attempts have been made to remove tumours from the canine brain and no doubt success will follow improvement in diagnosis and surgical technique. However, surgery is likely to have a limited application only because many of the gliomas are extremely invasive.
Conclusion: A wide variety of tumours of the brain occur in the dog, most commonly in the Boxer breed. Tumours may arise from the subependymal plate which may influence the parts of the brain destroyed and hence the pattern of clinical signs. Because of the small capacity of the dog's skull, vital neurological structures are quickly destroyed and the time course of these events is much shorter than in man. The high incidence of tumours in the Boxer would suggest that this breed might afford a useful model for clinical treatment using, for instance, cytotoxic agents. Although knowledge of the mechanisms involved in the blood-brain barrier remains inadequate there can be no doubt about its significance in clinical oncology. On the one hand it appears to exclude effective concentrations of most cytotoxic agents; on the other, it is frequently breached by neoplastic cells leading to meningeal leukemia or intracerebral metastasis formation.
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Yet it can be exploited. Radioisotope scanning depends on localized breaches of the barrier in the vicinity of intracerebral tumours. The evidence indicates that the new capillaries associated with tumour formation lack the tightjunctions, the so-called zonuke occludentes, which are found between the endothelial cells of normal brain capillaries (Long 1970 , Brightman et al. 1970 , Shuttleworth 1972 .
The importance of early diagnosis of both primary and secondary brain tumours is selfevident, for if treatment is to be effective in this anatomical site the lesion must be detected before irreversible damage has been incurred. Brain scans provide little or no information about the morphological nature of the lesion and both surgical resection and biopsy of cerebral lesions carry potentially severe penalties. The purpose of this paper is to draw attention to evidence which indicates that the blood/brain barrier provides a basis for biochemical and immunochemical methods for the detection of tumourassociated substances arising from tumours within the central nervous system (CNS).
One example, already tested to a limited degree, was proposed by Paoletti et al. (1969) . Desmosterol (24-dehydrocholesterol) is present in the cerebrospinal fluid (CSF) of some patients with gliomas. This substance is the precursor of cholesterol, and is present in large amounts in developing brain but only in small amounts in normal mature brain. Its concentration is increased by CNS tumours and the amount of desmosterol in CSF is further increased in these patients by the administration of triparaiiol which blocks its conversion to cholesterol. Positive results in 60-80% of patients with gliomas were confirmed by Weiss et al. (1972) , who considered the test to be potentially useful in patients with indecisive brain scans.
Enzymatic activity in spinal fluid provides another interesting example. Muramidase (lysozyme), a basic protein (mol. wt. 14 300) was found in CSF only in the presence of certain pathological processes which included intracranial tumours (Barone 1948) . Newman et al. (1974) have reported detectable levels of muramidase in 12 patients with primary or secondary CNS tumours but did not indicate whether they had any negative results. The source of the muramidase is uncertain and it may certainly originate from non-neoplastic cells (Mason & Roberts-Thomson 1974) . Nevertheless we need to know whether in the patient with known systemic malignant disease the detection of CSF muramidase might provide evidence of brain involvement.
Greater confidence and value would no doubt be attached to more specific markers. It is widely held that all human tumours, so far studied, are characterized by histogenic type-specific antigenic markers (Currie 1974) and that some of these antigenic products are exported by the tumour cells into body fluids. Carcinoembryonic antigen and a-fetoprotein are the well-known examples of export antigens, but the endocrine products of certain tumours have been studied in more detail, and the information with respect to human chorionic gonadotrophin (HCG) allows us to use it as a model for the wider problems.
In the 1930s gonadotrophic activity was detected by bioassay in'the CSF of patients with hydatidiform mole and choriocarcinoma, but not of pregnant women (Ehrhardt 1931 , Mathiew 1939 and later workers concluded that HCG only entered the CSF when a high threshold value was exceeded. Tashima et al. (1965) accepted the threshold concept but also found high HCG concentrations in CSF in 2 patients with intracerebral choriocarcinoma. Observations on a small part of the Charing Cross series , Rushworth et al. 1968 ) showed that with more sensitive assay techniques there was no threshold effect and, in the absence of brain metastases, there was a proportional relationship between the plasma and CSF concentrations of HCG over a wide range of values. In the presence of brain metastases the CSF concentration of HCG was disproportionately increased. In general therefore one has to consider-plasma/ CSF ratios rather than CSF concentration by itself.
Between 1964 and 1973 plasma and lumbar CSF samples have been analysed for HCG by radioimmunoassay (Wilde et al. 1967 ). In many samples of CSF the concentration was below the sensitivity level of the method 2-4 iu HCG/I. Detectable concentrations were recorded in 80 samples from 73 patients with gestational chorio-carcinoma and 16 samples from 5 patients with gonadotrophin-producing malignant teratomas who either survived without having evidence of brain metastasis at any time, or'who died and autopsy failed to reveal any evidence of intracerebral metastases. Samples were also obtained from 24 patients with gestational choriocarcinoma and 9 patients with gonadotrophin-producing malignant teratomas who had clinical brain scan and, in some cases, autopsy corroboration of brain metastases.
In the absence of brain metastases the plasma/ CSF HCG ratios for the gestational choriocarcinoma patients were in the range 64-1546 with a mean value of 286; for the malignant teratoma patients the range was 104-560, mean 208. The plasma/CSF ratios for patients with brain metastases, at the time clinical corroboration was obtained, were <60 in 24/26 patients with gestational choriocarcinoma and in 7/9 patients with malignant teratoma. The mean value for the 26 patients with intracerebral gestational choriocarcinoma was 22.4 and the range 0.5-107. For the 9 patients with cerebral teratoma the mean was 53, range 0.48-200. In 6 patients concentration of HCG in the CSF exceeded that in the plasma.
The 2 patients in the gestational group with initially normal values had presented 2-4 days earlier with hemiplegias of sudden onset and both had abnormal ratios when tested two weeks later. One of the 2 teratoma patients with normal ratios was found at autopsy to have a brain metastasis in which trophoblast could not be demonstrated though it was present in pulmonary metastases. An autopsy was not obtained on the other teratoma patient.
Several patients had plasma/CSF values estimated regularly before brain metastases were detected. Taking a value of <60 as significant, the plasma/CSF ratio gave advance warning of brain metastases in 13/17 patients with gestational choriocarcinoma and 1/2 teratoma patients, 1-20 weeks before clinical signs occurred. Normal ratios were found in 5 patients when tested 2-10 weeks before corroborative evidence but all had abnormal ratios (<60) when examined following the development of clinical signs or positive brain scans. Brain scans were not performed in the earlier part of the series and there has been no instance of positive brain scan with normal' plasma/CSF ratios but there have been 4 instances with one or more negative brain scans and abnormal HCG ratios which were subsequently corroborated. Serial measurements of plasma/ CSF ratios made it possible to monitor the effects of treatment on brain metastases.
In patients with intracerebral tumours, tumour products found in the CSF have a dual origin, Section ofOncology 53 part coming from the blood plasma due to systemic tumour and part by more direct export into cerebral ECF. Calculations can be made to subtract from the CSF HCG value the component attributable to diffusion from plasma and it remains to be determined whether this provides a better guide than plasma/CSF ratio.
Evidence that other intracranial tumours can be detected in this way is scanty, but it may be noted that thyroxine (Hansen & Siersbaek-Nielsen 1969) , arginine vasotocin (Pavel. 1970) and growth hormone (Linfoot et al. 1970 ) have been measured in CSF. In the case of growth hormone the CSF values reported for 3 patients with suprasellar extensions of pituitary tumours were higher than the plasma concentrations. Surprisingly, the authors attributed this to a breakdown of the blood/brain barrier.
These observations therefore raise the question of the operation of the blood/brain barrier with respect to products secreted by tumours. We have no information about the route of entry of HCG from blood into CSF and vice versa, but our evidence suggests that this is determined by concentration gradients, possibly across the capillary endothelium. In the case of cerebral tumours, if the lesion is located on or very close to the ventricular or meningeal surfaces there may be direct secretion into the CSF. In the case of lesions deep in the cerebral structure, the tumour products are presumably secreted into the small extracellular fluid (ECF) compartment. Presumably they may gain access from the ECF into the CSF since the reverse route from CSF into cerebral ECF, has been demonstrated by Brightman et al. (1970) for horseradish peroxidase which has a molecular weight of 43 000 comparable with that of HCG (40 000). In any case the fact that tumour products may be found in higher concentrations in CSF than in plasma rules out breakdown of the blood/brain barrier as the sole mechanism for their presence in CSF. The detection and measurement of tumour products in CSF may have a wide application when more of these substances have been characterized. 
Malignant Gliomas
The starting point of any discussion of management must be the natural history of the disease. Whether the natural history of any intracranial tumour can be ascertained is indeed doubtful, because without histological verification diagnosis cannot be assumed, while the very process of obtaining material for histological examination by burr hole biopsy or by craniotomy may significantly influence the patient's progress either favourably or adversely. The subsequent course cannot, therefore, be described as natural.
The long-accepted management of the patient with a supratentorial mass, demonstrated radiologically, has been the establishment of pathology and the removal of the tumour if benign. If malignant, and if access would not produce unacceptable deficit, the object of surgery has been to reduce tumour mass and thereby relieve intracranial pressure and distressing symptoms such as severe headache and failing visual acuity. It might improve level of consciousness, but was not expected to improve focal neurological deficit. Decisions about ease of access were not difficult, in that frontal pole, occipital pole and temporal lobe (particularly nondominant) masses were readily accessible. Midparietal or posterior parietal lesions were less accessible in that surgery was likely to produce unacceptable deficit, while deep lesions, particularly thalamic and callosal, were not accessible
